Compare AXGN & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | SUPN |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2013 | 2010 |
| Metric | AXGN | SUPN |
|---|---|---|
| Price | $48.18 | $43.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $42.33 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 776.6K | 581.4K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $225,208,000.00 | ★ $392,755,000.00 |
| Revenue This Year | $20.57 | $22.70 |
| Revenue Next Year | $16.68 | $19.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.21 | N/A |
| 52 Week Low | $15.27 | $42.45 |
| 52 Week High | $52.91 | $59.68 |
| Indicator | AXGN | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 41.02 |
| Support Level | $29.48 | $44.09 |
| Resistance Level | $52.91 | $52.33 |
| Average True Range (ATR) | 2.30 | 1.30 |
| MACD | -0.40 | -0.29 |
| Stochastic Oscillator | 30.89 | 19.63 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.